Skip to content


Sunitinib, a potent medication that falls under the category of Tyrosine Kinase Inhibitors, targets various signaling pathways to effectively block the activity of several tyrosine kinases (TKs) implicated in tumor growth and spread.
Specifically, sunitinib inhibits the TKs of Vascular Endothelial Growth Factor (VEGF), which disrupts the formation of new blood vessels crucial for tumor nourishment. Moreover, it targets Platelet-Derived Growth Factor (PDGF), leading to the destabilization and immaturity of existing blood vessels that support tumor growth.
Additionally, sunitinib blocks the activity of other tyrosine kinases including c-Kit, FLT3, Colony Stimulating Factor Receptor (SCF-1R), and RET. By concurrently targeting multiple receptor tyrosine kinases (RTKs), sunitinib disrupts abnormal cell signaling, effectively inhibiting the growth and proliferation of cancer cells, impeding the formation of new blood vessels in and around tumors, and restricting the migration of cancer cells.